Skip to main content

AIM ImmunoTech Inc.

AIM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946644

In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding AIM ImmunoTech Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of AIM: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders3412−22
SharesConverted for a 1-for-100 split48.3K12.1K−36.2K (−74.9%)
Value$590.0K$104.8K−$485.2K (−82.2%)

New holders (2)

Institutions that held AIM ImmunoTech Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to AIM in Q2 2025
InstitutionSharesValue% of portfolio
CI Private Wealth, LLC10,001$86.5K0.00%
Danske Bank A/S3$260.00%

Sold out (24)

Institutions that held AIM ImmunoTech Inc. at the end of Q1 2025 and filed for Q2 2025 without it.